Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900277 | 0.81 | SIGMAR1 (0.61) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL18574648 | 0.81 | SIGMAR1 (0.61) | SIGMAR1MC4RLMNAPOLBDRD4 | |
| SCHEMBL2507062 | 0.81 | SIGMAR1 (0.55) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL894392 | 0.80 | SIGMAR1 (0.59) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL14234158 | 0.78 | SIGMAR1 (0.52) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL893609 | 0.77 | SIGMAR1 (0.55) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL2489199 | 0.77 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL8188324 | 0.77 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL1415730 | 0.77 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL576868 | 0.77 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNAPOLBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182788-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4201936-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | disclosed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885MC4R 4341/4885LMNA 3272/4885 |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885MC4R 4341/4885LMNA 3272/4885 |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | SIGMAR1 4183/4885MC4R 3256/4885LMNA 1058/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885MC4R 4341/4885LMNA 3272/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3112/4885MC4R 3384/4885LMNA 3860/4885 |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | RET, BRAF, FGFR3 | SIGMAR1 4448/4885MC4R 2064/4885LMNA 3447/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885MC4R 3767/4885LMNA 4121/4885 |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885MC4R 4341/4885LMNA 3272/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3464/4885MC4R 3407/4885LMNA 3954/4885 |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885MC4R 4341/4885LMNA 3272/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885MC4R 3767/4885LMNA 4121/4885 |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | PPIP5K2, PIK3CA, PHKA1 | SIGMAR1 1436/4885MC4R 3876/4885LMNA 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.